In-depth immunophenotyping of patients with glioblastoma multiforme: Impact of steroid treatment
暂无分享,去创建一个
S. Freitag-Wolf | O. Janssen | H. Oberg | D. Kabelitz | M. Synowitz | Stefanie Luecke | C. Flüh | J. Held-Feindt | M. Lettau | E. Quabius | C. Peters | D. Wesch | G. Chitadze | J. Bhat | Jaydeep Bhat
[1] H. Oberg,et al. The Ambiguous Role of γδ T Lymphocytes in Antitumor Immunity. , 2017, Trends in immunology.
[2] Xiaopei Huang,et al. IL‐18‐dependent NKG2D ligand upregulation on accessory cells is mediated by the PI3K/GSK‐3 pathway , 2017, Journal of leukocyte biology.
[3] V. Yong,et al. T Cell Exhaustion in Glioblastoma: Intricacies of Immune Checkpoints. , 2017, Trends in immunology.
[4] M. Ebsen,et al. Monitoring and functional characterization of the lymphocytic compartment in pancreatic ductal adenocarcinoma patients. , 2016, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].
[5] J. Prehn,et al. Advances in immunotherapy for the treatment of glioblastoma , 2016, Journal of Neuro-Oncology.
[6] G. Liang,et al. Rescuing defective tumor-infiltrating T-cell proliferation in glioblastoma patients. , 2016, Oncology letters.
[7] Cornelis J. Stam,et al. Random forest to differentiate dementia with Lewy bodies from Alzheimer's disease , 2016, Alzheimer's & dementia.
[8] J. Brahmer,et al. Using Immune Checkpoint Inhibitors in Lung Cancer. , 2016, Oncology.
[9] C. L. da Silva,et al. Delta One T Cells for Immunotherapy of Chronic Lymphocytic Leukemia: Clinical-Grade Expansion/Differentiation and Preclinical Proof of Concept , 2016, Clinical Cancer Research.
[10] Yufeng Shen,et al. Diversity and divergence of the glioma-infiltrating T-cell receptor repertoire , 2016, Proceedings of the National Academy of Sciences.
[11] B. Pineda,et al. Immunological Evasion in Glioblastoma , 2016, BioMed research international.
[12] J. C. Love,et al. PD-1 marks dysfunctional regulatory T cells in malignant gliomas. , 2016, JCI insight.
[13] M. Bonneville,et al. Stereotaxic administrations of allogeneic human Vγ9Vδ2 T cells efficiently control the development of human glioblastoma brain tumors , 2016, Oncoimmunology.
[14] S. Razavi,et al. Immune Evasion Strategies of Glioblastoma , 2016, Front. Surg..
[15] K. Kesavabhotla,et al. Immunomonitoring in glioma immunotherapy: current status and future perspectives , 2016, Journal of Neuro-Oncology.
[16] A. Ludwig,et al. Transmembrane chemokines act as receptors in a novel mechanism termed inverse signaling , 2016, eLife.
[17] O. Janssen,et al. NKG2D- and T-cell receptor-dependent lysis of malignant glioma cell lines by human γδ T cells: Modulation by temozolomide and A disintegrin and metalloproteases 10 and 17 inhibitors , 2015, Oncoimmunology.
[18] G. Finocchiaro,et al. The multidrug-resistance transporter Abcc3 protects NK cells from chemotherapy in a murine model of malignant glioma , 2015, Oncoimmunology.
[19] M. Valsecchi. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.
[20] Qingchang Li,et al. Pre-treatment neutrophil-to-lymphocyte ratio is associated with neutrophil and T-cell infiltration and predicts clinical outcome in patients with glioblastoma , 2015, BMC Cancer.
[21] S. Gautam,et al. Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma , 2015, British Journal of Cancer.
[22] R. Kast. The role of interleukin-18 in glioblastoma pathology implies therapeutic potential of two old drugs—disulfiram and ritonavir , 2015, Chinese journal of cancer.
[23] M. Bodman-smith,et al. Harnessing the power of Vδ2 cells in cancer immunotherapy , 2015, Clinical and experimental immunology.
[24] Jennifer D. Wu,et al. NKG2D Ligands in Tumor Immunity: Two Sides of a Coin , 2015, Front. Immunol..
[25] L. Pereboeva,et al. The safety of allogeneic innate lymphocyte therapy for glioma patients with prior cranial irradiation , 2015, Cancer Immunology, Immunotherapy.
[26] Y. Lau,et al. Targeted activation of human Vγ9Vδ2-T cells controls epstein-barr virus-induced B cell lymphoproliferative disease. , 2014, Cancer cell.
[27] M. Bachmann,et al. A Truncated Human NKG2D Splice Isoform Negatively Regulates NKG2D-Mediated Function , 2014, The Journal of Immunology.
[28] L. Avanesyan,et al. Immune evasion mediated by tumor-derived lactate dehydrogenase induction of NKG2D ligands on myeloid cells in glioblastoma patients , 2014, Proceedings of the National Academy of Sciences.
[29] L. Lamb,et al. Cytotoxic and regulatory properties of circulating Vδ1+ γδ T cells: a new player on the cell therapy field? , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.
[30] G. Vartholomatos,et al. Prognostic value of the preoperative immunological profile in patients with glioblastoma , 2014, Surgical neurology international.
[31] D. Kabelitz,et al. Neutrophil uptake of nitrogen-bisphosphonates leads to the suppression of human peripheral blood γδ T cells , 2013, Cellular and Molecular Life Sciences.
[32] S. V. Van Gool,et al. Dendritic cell vaccination for glioblastoma multiforme: review with focus on predictive factors for treatment response , 2014, ImmunoTargets and therapy.
[33] Taosheng Chen,et al. Modulation of NKG2D ligand expression and metastasis in tumors by spironolactone via RXRγ activation , 2013, The Journal of experimental medicine.
[34] J. Zimmer,et al. Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level , 2013, Journal of Neuroimmunology.
[35] O. Janssen,et al. Shedding of endogenous MHC class I‐related chain molecules A and B from different human tumor entities: Heterogeneous involvement of the “a disintegrin and metalloproteases” 10 and 17 , 2013, International journal of cancer.
[36] W. Britt,et al. CMV-Independent Lysis of Glioblastoma by Ex Vivo Expanded/Activated Vδ1+ γδ T Cells , 2013, PloS one.
[37] O. Janssen,et al. Generation of Soluble NKG2D Ligands: Proteolytic Cleavage, Exosome Secretion and Functional Implications , 2013, Scandinavian journal of immunology.
[38] A. Dasgupta,et al. Engineered Drug Resistant γδ T Cells Kill Glioblastoma Cell Lines during a Chemotherapy Challenge: A Strategy for Combining Chemo- and Immunotherapy , 2013, PloS one.
[39] S. Sengupta,et al. Impact of Temozolomide on Immune Response during Malignant Glioma Chemotherapy , 2012, Clinical & developmental immunology.
[40] B. Kaina,et al. Human Monocytes Undergo Excessive Apoptosis following Temozolomide Activating the ATM/ATR Pathway While Dendritic Cells and Macrophages Are Resistant , 2012, PloS one.
[41] W. Fu,et al. A forward loop between glioma and microglia: Glioma‐derived extracellular matrix‐activated microglia secrete IL‐18 to enhance the migration of glioma cells , 2012, Journal of cellular physiology.
[42] A. Bagg,et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.
[43] J. Gui,et al. Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme. , 2011, Neuro-oncology.
[44] S. Pastorino,et al. Corticosteroids in brain cancer patients: benefits and pitfalls , 2011, Expert review of clinical pharmacology.
[45] S. Grace,et al. The role of Vδ2-negative γδ T cells during cytomegalovirus reactivation in recipients of allogeneic stem cell transplantation. , 2010, Blood.
[46] Witold R. Rudnicki,et al. Feature Selection with the Boruta Package , 2010 .
[47] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[48] Changlian Zhu,et al. Irradiation to the immature brain attenuates neurogenesis and exacerbates subsequent hypoxic‐ischemic brain injury in the adult , 2009, Journal of neurochemistry.
[49] J. Markert,et al. Characterization and immunotherapeutic potential of gammadelta T-cells in patients with glioblastoma. , 2009, Neuro-oncology.
[50] J. Mönkkönen,et al. Peripheral blood monocytes are responsible for γδ T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP , 2009, British journal of haematology.
[51] Santosh Kesari,et al. Malignant gliomas in adults. , 2008, The New England journal of medicine.
[52] U. Beuers,et al. Soluble NKG2D ligands in hepatic autoimmune diseases and in benign diseases involved in marker metabolism. , 2007, Anticancer research.
[53] C. Cobbs,et al. Human cytomegalovirus induces cellular tyrosine kinase signaling and promotes glioma cell invasiveness , 2007, Journal of Neuro-Oncology.
[54] M. Gobbi,et al. Expansion of Vdelta1 T lymphocytes producing IL-4 in low-grade non-Hodgkin lymphomas expressing UL-16-binding proteins. , 2007, Blood.
[55] M. Weller,et al. TGF-β and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells , 2006 .
[56] Paul F. Meeh,et al. Characterization of the γδ T cell response to acute leukemia , 2006, Cancer Immunology, Immunotherapy.
[57] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[58] M. Gobbi,et al. Vδ1 T Lymphocytes from B-CLL Patients Recognize ULBP3 Expressed on Leukemic B Cells and Up-Regulated by Trans-Retinoic Acid , 2004, Cancer Research.
[59] K. Sepkowitz,et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[60] G. De Libero,et al. Human T Cell Receptor γδ Cells Recognize Endogenous Mevalonate Metabolites in Tumor Cells , 2003, The Journal of experimental medicine.
[61] M. Caligiuri,et al. The biology of human natural killer-cell subsets. , 2001, Trends in immunology.
[62] Leo Breiman,et al. Random Forests , 2001, Machine Learning.
[63] M. Caligiuri,et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset , 2001 .
[64] M. Bonneville,et al. Implication of γδ T cells in the human immune response to cytomegalovirus , 1999 .
[65] M. Bonneville,et al. Implication of gammadelta T cells in the human immune response to cytomegalovirus. , 1999, The Journal of clinical investigation.
[66] J. Hogg,et al. Glucocorticoid-induced granulocytosis: contribution of marrow release and demargination of intravascular granulocytes. , 1998, Circulation.
[67] G. Cox,et al. Glucocorticoid treatment inhibits apoptosis in human neutrophils. Separation of survival and activation outcomes. , 1995, Journal of immunology.
[68] A. Fauci. Mechanisms of corticosteroid action on lymphocyte subpopulations. II. Differential effects of in vivo hydrocortisone, prednisone and dexamethasone on in vitro expression of lymphocyte function. , 1976, Clinical and experimental immunology.
[69] N. Amariglio,et al. Peripheral blood-derived, γ9δ2 t cell-enriched cell lines from glioblastoma multiforme patients exert anti-tumoral effects in vitro. , 2016, Journal of biological regulators and homeostatic agents.
[70] G. Lessiani,et al. PERIPHERAL BLOOD-DERIVED , γ 9 δ 2 T CELL-ENRICHED CELL LINES FROM GLIOBLASTOMA MULTIFORME PATIENTS EXERT ANTI-TUMORAL EFFECTS IN VITRO , 2016 .
[71] I. Nakagawa,et al. Cytotoxic human peripheral blood-derived γδT cells kill glioblastoma cell lines: implications for cell-based immunotherapy for patients with glioblastoma , 2013, Journal of Neuro-Oncology.
[72] D. Baarle,et al. γδT cells elicited by CMV reactivation after allo-SCT cross-recognize CMV and leukemia , 2013, Leukemia.
[73] W. Britt,et al. CMV-Independent Lysis of Glioblastoma by Ex VivoExpanded/Activated Vdelta1+ gamma-delta T Cells , 2013 .
[74] J. Markert,et al. Preclinical evaluation of ex vivo expanded/activated γδ T cells for immunotherapy of glioblastoma multiforme , 2010, Journal of Neuro-Oncology.
[75] David Sugden,et al. Quantification of mRNA Using Real Time RT-PCR , 2008 .
[76] M. Weller,et al. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. , 2006, Brain : a journal of neurology.
[77] Paul F. Meeh,et al. Characterization of the gammadelta T cell response to acute leukemia. , 2006, Cancer immunology, immunotherapy : CII.
[78] M. Weller,et al. TGF-b and metalloproteinases differentially suppress NKG 2 D ligand surface expression on malignant glioma cells , 2006 .
[79] M. Gobbi,et al. Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid. , 2004, Cancer research.
[80] T. Ghayur,et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. , 2001, Blood.
[81] J. Hogg,et al. L-selectin expression on polymorphonuclear leukocytes and monocytes in premature infants: reduced expression after dexamethasone treatment for bronchopulmonary dysplasia. , 1998, The Journal of pediatrics.
[82] A. Dasgupta,et al. Engineered Drug Resistant gamma delta T Cells Kill Glioblastoma Cell Lines during a Chemotherapy Challenge: A Strategy for Combining Chemo-and Immunotherapy , 2022 .